HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

RTI 55 (Iometopane)

structure given in first source; a dopamine transporter ligand; RN given refers to (1R-(exo,exo))-isomer

Also Known As:

Iometopane; 2-carbomethoxy-3-(4-iodophenyl)tropane; 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; 3-(4-iodophenyl)tropane-2-carboxylic acid methyl ester; I(123)beta-CIT; Iodine (125)-RTI-55; RTI 55, (11)C-labeled, (1R-(exo,exo))-isomer; RTI 55, (exo,exo)-isomer, (123)I-labeled; RTI-55; beta-CIT

Networked: 109 relevant articles (2 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pirker, Walter: 7 articles (12/2004 - 01/2002)
2.	Brücke, Thomas: 5 articles (09/2005 - 01/2002)
3.	Brücke, T: 5 articles (07/2002 - 03/2000)
4.	Pirker, W: 5 articles (07/2002 - 03/2000)
5.	Asenbaum, S: 5 articles (02/2001 - 03/2000)
6.	Barthel, Henryk: 4 articles (01/2006 - 08/2002)
7.	Sabri, Osama: 4 articles (01/2006 - 08/2002)
8.	Hesse, Swen: 4 articles (01/2006 - 08/2002)
9.	Asenbaum, Susanne: 4 articles (11/2003 - 01/2002)
10.	Gerschlager, Willibald: 4 articles (11/2003 - 01/2002)

Related Diseases

1.	Flushing 03/01/2014 - "[(123)I]-Beta-CIT reduction was associated with BDI reduction (r(2)=0.54; F=8.8; p=0.004), but not flushing reduction or perfusion reduction. " 03/01/2014 - "Following treatment with venlafaxine, there was a significant reduction in the [(123)I]-beta-CIT binding ratio, BDI scores, flushing and endothelial dependent perfusion response. " 03/01/2014 - "Venlafaxine alters microvascular perfusion, [¹²³I]-beta-CIT binding and BDI scores in flushing postmenopausal women."
2.	Body Weight (Weight, Body) 01/01/1995 - "A highly significant reduction of beta-CIT binding was found in an area including mesial thalamus, hypothalamus, midbrain and pons in patients under citalopram compared to controls (44.1 +/- 14.4 vs. 82.3 +/- 18.6cpm's/mCi x kg body weight; specific binding 4 hrs p.inj.; p = 0.0001). "
3.	Parkinson Disease (Parkinson's Disease) 01/01/2003 - "We used single photon emission computed tomography (SPECT) to study striatal [(123)I]beta-CIT binding and polysomnography to study periodic leg movements during sleep (PLMS) in eleven patients with idiopathic Parkinson's disease (PD). " 07/01/1999 - "Detection of preclinical Parkinson disease in at-risk family members with use of [123I]beta-CIT and SPECT: an exploratory study." 02/01/1997 - "[123I]beta-CIT single photon emission computed tomography (SPECT) studies have demonstrated this loss of striatal DA transporter content in Parkinson's disease in vivo. " 10/01/1995 - "Previous studies have utilized single-photon emission computed tomography (SPECT) to demonstrate decreased [123I]beta-CIT striatal uptake in idiopathic Parkinson disease (PD) patients. " 01/01/2006 - "Iodine-123 ((123)I) (2beta-carboxymethoxy-3beta-[4-iodophenyl] tropane) or ((123)I) beta-CIT is a recently developed diagnostic biomarker of Parkinson's disease that provides in vivo information about nigrostriatal degeneration. "
4.	Parkinsonian Disorders (Parkinsonism) 12/01/2002 - "The purpose of this study was to evaluate the impact of [(123)I]-beta-CIT SPET on the diagnosis and clinical management of patients with a primary, tentative diagnosis of parkinsonism. " 08/01/2006 - "Midbrain [(123)I]beta-CIT uptake discriminated atypical parkinsonian disorders from PD with an overall correct classification of 91.3%. " 08/01/2006 - "All patients with the different parkinsonian disorders showed a significant decrease in striatal [(123)I]beta-CIT uptake without any overlap with the control group. " 07/01/2005 - "We suggest that the quantification of midbrain DAT signal should be included in the routine clinical analysis of [123I]beta-CIT SPECT in patients with uncertain parkinsonism." 10/01/2004 - "Bilateral akinetic-rigid parkinsonism was found in only one patient whose [(123)I]beta-CIT-SPECT showed a decrease of the ligand uptake following the limits of the vascular lesion. "
5.	Multiple System Atrophy 11/01/2001 - "This study has examined and compared the loss of striatal DAT in PD and multiple system atrophy (MSA) using [(123)I]beta-CIT SPECT imaging. " 07/01/2005 - "Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease." 11/01/2000 - "[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration." 07/01/2005 - "To investigate the cerebral dopamine transporter status in the early stages of the parkinson-variant of multiple system atrophy (MSA-P), 15 patients with MSA-P and a disease duration up to 3 years were studied with [123I]beta-CIT single photon emission computed tomography (SPECT). " 01/01/2000 - "SPECT scans were acquired in 9 patients with sOPCA, 7 multiple system atrophy (MSA) patients with parkinsonism (MSA-P), and 7 age-matched healthy controls 20-24 h after the intravenous injection of [(123)I]beta-CIT. "

Related Drugs and Biologics

1.	Citalopram (Escitalopram)
2.	venlafaxine (Effexor)
3.	Dopamine (Intropin)
4.	Serotonin (5 Hydroxytryptamine)
5.	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
6.	Cocaine (Cocaine HCl)
7.	Levodopa (L Dopa)
8.	epidepride
9.	3- iodo- 2- hydroxy- 6- methoxy- N- ((1- ethyl- 2- pyrrolidinyl)methyl)benzamide
10.	Dihydroxyphenylalanine (Dopa)

Related Therapies and Procedures

1.	Spinal Injections
2.	Activities of Daily Living (ADL)
3.	Gamma Cameras (Gamma Camera)
4.	Intravenous Injections
5.	Aftercare (After-Treatment)